1.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

2.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

3.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

4.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

5.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

6.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

7.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

8.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

9.

Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium

1.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

2.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

3.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

4.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

5.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

6.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017.

1.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

2.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

3.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

4.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

5.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

6.

Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017

1.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study

2.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study

3.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study

4.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study

1.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

2.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

3.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

4.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

5.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

6.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

7.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

8.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

9.

Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study

1.

A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real...

2.

A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real...

3.

A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real...

4.

A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real...

1.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

2.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

3.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

4.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

5.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

6.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

7.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

8.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

9.

Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care

1.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

2.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

3.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

4.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

5.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

6.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

7.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

8.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

9.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

1.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

2.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

3.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

4.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

5.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

6.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

7.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

8.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

9.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.